Phalangeal microgeodic syndrome: case report of a  young woman treated with pentoxifylline
We report the case of a young woman presenting with joint pain in her feet, along with toe discoloration and redness, where a diagnosis of PMS was established based on magnetic resonance imaging findings and exclusion of other differential diagnostic entities. Pharmacological treatment was deemed necessary for symptomatic relief, but a trial of calcium channel blocker (CCB) was not tolerated by the patient. The patient was then started on pentoxifylline, with significant clinical improvement.PMID:38175270 | DOI:10.1007/s00393-023-01470-y (Source: Zeitschrift fur Rheumatologie)
Source: Zeitschrift fur Rheumatologie - January 4, 2024 Category: Rheumatology Authors: Tiago Borges Miguel Castro Source Type: research

Phalangeal microgeodic syndrome: case report of a  young woman treated with pentoxifylline
We report the case of a young woman presenting with joint pain in her feet, along with toe discoloration and redness, where a diagnosis of PMS was established based on magnetic resonance imaging findings and exclusion of other differential diagnostic entities. Pharmacological treatment was deemed necessary for symptomatic relief, but a trial of calcium channel blocker (CCB) was not tolerated by the patient. The patient was then started on pentoxifylline, with significant clinical improvement.PMID:38175270 | DOI:10.1007/s00393-023-01470-y (Source: Zeitschrift fur Rheumatologie)
Source: Zeitschrift fur Rheumatologie - January 4, 2024 Category: Rheumatology Authors: Tiago Borges Miguel Castro Source Type: research

Phalangeal microgeodic syndrome: case report of a  young woman treated with pentoxifylline
We report the case of a young woman presenting with joint pain in her feet, along with toe discoloration and redness, where a diagnosis of PMS was established based on magnetic resonance imaging findings and exclusion of other differential diagnostic entities. Pharmacological treatment was deemed necessary for symptomatic relief, but a trial of calcium channel blocker (CCB) was not tolerated by the patient. The patient was then started on pentoxifylline, with significant clinical improvement.PMID:38175270 | DOI:10.1007/s00393-023-01470-y (Source: Zeitschrift fur Rheumatologie)
Source: Zeitschrift fur Rheumatologie - January 4, 2024 Category: Rheumatology Authors: Tiago Borges Miguel Castro Source Type: research

Phalangeal microgeodic syndrome: case report of a  young woman treated with pentoxifylline
We report the case of a young woman presenting with joint pain in her feet, along with toe discoloration and redness, where a diagnosis of PMS was established based on magnetic resonance imaging findings and exclusion of other differential diagnostic entities. Pharmacological treatment was deemed necessary for symptomatic relief, but a trial of calcium channel blocker (CCB) was not tolerated by the patient. The patient was then started on pentoxifylline, with significant clinical improvement.PMID:38175270 | DOI:10.1007/s00393-023-01470-y (Source: Zeitschrift fur Rheumatologie)
Source: Zeitschrift fur Rheumatologie - January 4, 2024 Category: Rheumatology Authors: Tiago Borges Miguel Castro Source Type: research

Phalangeal microgeodic syndrome: case report of a  young woman treated with pentoxifylline
We report the case of a young woman presenting with joint pain in her feet, along with toe discoloration and redness, where a diagnosis of PMS was established based on magnetic resonance imaging findings and exclusion of other differential diagnostic entities. Pharmacological treatment was deemed necessary for symptomatic relief, but a trial of calcium channel blocker (CCB) was not tolerated by the patient. The patient was then started on pentoxifylline, with significant clinical improvement.PMID:38175270 | DOI:10.1007/s00393-023-01470-y (Source: Zeitschrift fur Rheumatologie)
Source: Zeitschrift fur Rheumatologie - January 4, 2024 Category: Rheumatology Authors: Tiago Borges Miguel Castro Source Type: research

Advances in the diagnostics and treatment of juvenile dermatomyositis
Z Rheumatol. 2023 Dec 29. doi: 10.1007/s00393-023-01454-y. Online ahead of print.ABSTRACTJuvenile dermatomyositis (JDM) is by far the most frequent inflammatory myopathy in childhood and adolescence. It is clinically characterized by inflammatory changes of the skin and muscles but as a multisystemic disease can also affect the skeletal system, the gastrointestinal tract, lungs and heart. Intrinsic (multigenetic risk) and extrinsic factors (triggers) are involved in the pathogenesis resulting in endothelial damage, involvement of fascies, activation of the interferon system and autoimmune reactions including formation of m...
Source: Zeitschrift fur Rheumatologie - December 29, 2023 Category: Rheumatology Authors: Ingrid Georgi Mathias Georgi Johannes-Peter Haas Source Type: research

Protocols in pediatric rheumatology (PROKIND): treat-to-target in polyarticular juvenile idiopathic arthritis
CONCLUSION: Using a treat-to-target approach a dramatic improvement in disease activity, functional capacity and quality of life in polyarticular JIA could be achieved. Even after 12 months an inactive disease was achieved in the majority of cases.PMID:38157052 | DOI:10.1007/s00393-023-01452-0 (Source: Zeitschrift fur Rheumatologie)
Source: Zeitschrift fur Rheumatologie - December 29, 2023 Category: Rheumatology Authors: G Horneff K Minden D Foell J Klotsche K Tenbrock PROKIND-Arbeitsgruppe Source Type: research

Safety and efficacy of telitacicept in refractory systemic lupus erythematosus patients who failed treatment with belimumab : A  case series
CONCLUSION: This is the first case series in SLE patients who accepted telitacicept treatment after failed treatment with belimumab. Our case series and review of the literature show that telitacicept combined with the original standard treatment may significantly improve disease activity while reducing prednisone use. No major safety issues were seen in this group of patients. Telitacicept may be a promising drug for the treatment of refractory lupus hepatitis.PMID:38157053 | DOI:10.1007/s00393-023-01461-z (Source: Zeitschrift fur Rheumatologie)
Source: Zeitschrift fur Rheumatologie - December 29, 2023 Category: Rheumatology Authors: Qiuyu Fan Huiqin Yang Ya Liu Source Type: research

Advances in the diagnostics and treatment of juvenile dermatomyositis
Z Rheumatol. 2023 Dec 29. doi: 10.1007/s00393-023-01454-y. Online ahead of print.ABSTRACTJuvenile dermatomyositis (JDM) is by far the most frequent inflammatory myopathy in childhood and adolescence. It is clinically characterized by inflammatory changes of the skin and muscles but as a multisystemic disease can also affect the skeletal system, the gastrointestinal tract, lungs and heart. Intrinsic (multigenetic risk) and extrinsic factors (triggers) are involved in the pathogenesis resulting in endothelial damage, involvement of fascies, activation of the interferon system and autoimmune reactions including formation of m...
Source: Zeitschrift fur Rheumatologie - December 29, 2023 Category: Rheumatology Authors: Ingrid Georgi Mathias Georgi Johannes-Peter Haas Source Type: research

Protocols in pediatric rheumatology (PROKIND): treat-to-target in polyarticular juvenile idiopathic arthritis
CONCLUSION: Using a treat-to-target approach a dramatic improvement in disease activity, functional capacity and quality of life in polyarticular JIA could be achieved. Even after 12 months an inactive disease was achieved in the majority of cases.PMID:38157052 | DOI:10.1007/s00393-023-01452-0 (Source: Zeitschrift fur Rheumatologie)
Source: Zeitschrift fur Rheumatologie - December 29, 2023 Category: Rheumatology Authors: G Horneff K Minden D Foell J Klotsche K Tenbrock PROKIND-Arbeitsgruppe Source Type: research

Safety and efficacy of telitacicept in refractory systemic lupus erythematosus patients who failed treatment with belimumab : A  case series
CONCLUSION: This is the first case series in SLE patients who accepted telitacicept treatment after failed treatment with belimumab. Our case series and review of the literature show that telitacicept combined with the original standard treatment may significantly improve disease activity while reducing prednisone use. No major safety issues were seen in this group of patients. Telitacicept may be a promising drug for the treatment of refractory lupus hepatitis.PMID:38157053 | DOI:10.1007/s00393-023-01461-z (Source: Zeitschrift fur Rheumatologie)
Source: Zeitschrift fur Rheumatologie - December 29, 2023 Category: Rheumatology Authors: Qiuyu Fan Huiqin Yang Ya Liu Source Type: research

Advances in the diagnostics and treatment of juvenile dermatomyositis
Z Rheumatol. 2023 Dec 29. doi: 10.1007/s00393-023-01454-y. Online ahead of print.ABSTRACTJuvenile dermatomyositis (JDM) is by far the most frequent inflammatory myopathy in childhood and adolescence. It is clinically characterized by inflammatory changes of the skin and muscles but as a multisystemic disease can also affect the skeletal system, the gastrointestinal tract, lungs and heart. Intrinsic (multigenetic risk) and extrinsic factors (triggers) are involved in the pathogenesis resulting in endothelial damage, involvement of fascies, activation of the interferon system and autoimmune reactions including formation of m...
Source: Zeitschrift fur Rheumatologie - December 29, 2023 Category: Rheumatology Authors: Ingrid Georgi Mathias Georgi Johannes-Peter Haas Source Type: research

Protocols in pediatric rheumatology (PROKIND): treat-to-target in polyarticular juvenile idiopathic arthritis
CONCLUSION: Using a treat-to-target approach a dramatic improvement in disease activity, functional capacity and quality of life in polyarticular JIA could be achieved. Even after 12 months an inactive disease was achieved in the majority of cases.PMID:38157052 | DOI:10.1007/s00393-023-01452-0 (Source: Zeitschrift fur Rheumatologie)
Source: Zeitschrift fur Rheumatologie - December 29, 2023 Category: Rheumatology Authors: G Horneff K Minden D Foell J Klotsche K Tenbrock PROKIND-Arbeitsgruppe Source Type: research

Safety and efficacy of telitacicept in refractory systemic lupus erythematosus patients who failed treatment with belimumab : A  case series
CONCLUSION: This is the first case series in SLE patients who accepted telitacicept treatment after failed treatment with belimumab. Our case series and review of the literature show that telitacicept combined with the original standard treatment may significantly improve disease activity while reducing prednisone use. No major safety issues were seen in this group of patients. Telitacicept may be a promising drug for the treatment of refractory lupus hepatitis.PMID:38157053 | DOI:10.1007/s00393-023-01461-z (Source: Zeitschrift fur Rheumatologie)
Source: Zeitschrift fur Rheumatologie - December 29, 2023 Category: Rheumatology Authors: Qiuyu Fan Huiqin Yang Ya Liu Source Type: research

Why the regeneration of immunological tolerance by vaccination is difficult
Z Rheumatol. 2023 Dec 18. doi: 10.1007/s00393-023-01453-z. Online ahead of print.ABSTRACTAutoimmunity, including that involved in chronic inflammatory rheumatic diseases, seems to be the price we have to pay for our efficient immune system. It has the ability to precisely recognize pathogens and tumor cells, to efficiently fight them, to adapt to their alterations and provide specific immunity for a lifetime. "Inoculation", and more specifically "vaccination" takes advantage of this, either by transfer of protective antibodies (passive vaccination) or by using attenuated pathogens or parts of them by which a specific prote...
Source: Zeitschrift fur Rheumatologie - December 19, 2023 Category: Rheumatology Authors: Andreas Radbruch Fritz Melchers Source Type: research